Biological Activity of α-MSH–Peptide Conjugates

Ildikó Szabó,Beáta Biri-Kovács,Balázs Vári,Ivan Ranđelović,Diána Vári-Mező,Éva Juhász,Gábor Halmos,Szilvia Bősze,József Tóvári,Gábor Mező

DOI: https://doi.org/10.3390/ijms25021095

IF: 5.6

2024-01-16

International Journal of Molecular Sciences

Abstract:Malignant melanoma is one of the most aggressive and resistant tumor types, with high metastatic properties. Because of the lack of suitable chemotherapeutic agents for treatment, the 5-year survival rate of melanoma patients with regional and distant metastases is lower than 10%. Targeted tumor therapy that provides several promising results might be a good option for the treatment of malignant melanomas. Our goal was to develop novel melanoma-specific peptide–drug conjugates for targeted tumor therapy. Melanocortin-1-receptor (MC1R) is a cell surface receptor responsible for melanogenesis and it is overexpressed on the surface of melanoma cells, providing a good target. Its native ligand, α-MSH (α-melanocyte-stimulating hormone) peptide, or its derivatives, might be potential homing devices for this purpose. Therefore, we prepared three α-MSH derivative–daunomycin (Dau) conjugates and their in vitro and in vivo antitumor activities were compared. Dau has an autofluorescence property; therefore, it is suitable for preparing conjugates for in vitro (e.g., cellular uptake) and in vivo experiments. Dau was attached to the peptides via a non-cleavable oxime linkage that was applied efficiently in our previous experiments, resulting in conjugates with high tumor growth inhibition activity. The results indicated that the most promising conjugate was the compound in which Dau was connected to the side chain of Lys (Ac-SYSNleEHFRWGK(Dau=Aoa)PV-NH2). The highest cellular uptake by melanoma cells was demonstrated using the compound, with the highest tumor growth inhibition detected both on mouse (38.6% on B16) and human uveal melanoma (55% on OMC-1) cells. The effect of the compound was more pronounced than that of the free drug.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

This paper aims to solve the key problems in the treatment of malignant melanoma. Malignant melanoma is a very invasive and drug - resistant type of tumor with high metastatic characteristics. Due to the lack of effective chemotherapeutic drugs, the 5 - year survival rate of patients with malignant melanoma is less than 10% in the case of regional or distant metastasis. Therefore, researchers are committed to developing new targeted treatment strategies to improve the treatment effect. Specifically, the goal of this study is to develop new melanoma - specific peptide - drug conjugates for targeted tumor treatment. The focus of the study is on the Melanocortin - 1 - receptor (MC1R), a cell - surface receptor responsible for melanin production, which is over - expressed on the surface of melanoma cells and provides a good target. Its natural ligand α - MSH (α - melanocyte - stimulating hormone) or its derivatives may serve as potential homing devices for targeted therapy. To achieve this goal, the researchers prepared three conjugates of α - MSH derivatives and daunomycin (Dau) and compared their anti - tumor activities in vitro and in vivo. Dau has autofluorescence properties and is therefore suitable for preparing conjugates for in vitro (such as cell uptake) and in vivo experiments. Dau is linked to the peptide via an uncleavable oxime bond, which has been proven to be efficient in previous experiments and can produce conjugates with high tumor growth - inhibitory activity. The study shows that the most promising conjugate is the compound (Ac - SYSNleEHFRWGK(Dau = Aoa)PV - NH₂) in which Dau is linked to the Lys side chain. This compound has the highest uptake in melanoma cells and exhibits the highest tumor growth - inhibitory effects in mouse (B16 cell line) and human ocular melanoma (OMC - 1 cell line) cells, with 38.6% and 55% respectively. In addition, the effect of this compound is more significant than that of the free drug. In conclusion, this paper attempts to solve the problems in the treatment of malignant melanoma and improve the treatment effect by developing conjugates of α - MSH derivatives and daunomycin.

Biological Activity of α-MSH–Peptide Conjugates

Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA

Discovery of novel peptide–dehydroepiandrosterone hybrids inducing endoplasmic reticulum stress with effective in vitro and in vivo anti-melanoma activities

In vitro and in vivo evaluation of Bombesin-MMAE conjugates for targeted tumour therapy

Tumor-cell-targeted methionine-enkephalin analogues containing unnatural amino acids: design, synthesis, and in vitro antitumor activity

Novel Allosteric Inhibitors of Deoxyhypusine Synthase against Malignant Melanoma: Design, Synthesis, and Biological Evaluation

Amyloid-like aggregates of short self-assembly peptide selectively induce melanoma cell apoptosis

Synthesis and Anti‐Melanoma Activity of Acryloyl Pyridinone Analogues

Novel, cysteine-modified chelation strategy for the incorporation of [MI(CO)3]+ (M = Re, 99mTc) in an α-MSH peptide

Synthetic Melanin Acts as Efficient Peptide Carrier in Cancer Vaccine Strategy

Evaluation of an (111)In-DOTA-rhenium cyclized alpha-MSH analog: a novel cyclic-peptide analog with improved tumor-targeting properties.

Synthesis and evaluation of bivalent ligands for binding to the human melanocortin-4 receptor

Therapeutic Effect of Melittin-dKLA Targeting Tumor-Associated Macrophages in Melanoma

Synthesis and Biological Evaluation of Novel N, N′-disubstituted Urea and Thiourea Derivatives As Potential Anti-Melanoma Agents

Comparative Study of the Potential Cell-Penetrating Peptide ∆M4 on Apoptosis Cell Signaling in A375 and A431 Cancer Cell Lines

Mitochondrial Voltage-Dependent Anion Channel 1–Hexokinase-II Complex-Targeted Strategy for Melanoma Inhibition Using Designed Multiblock Peptide Amphiphiles

Novel Cocrystal Structures of Peptide Antagonists Bound to the Human Melanocortin Receptor 4 Unveil Unexplored Grounds for Structure-Based Drug Design

Recent Advances in the Antiproliferative and Proapoptotic Activity of Various Plant Extracts and Constituents against Murine Malignant Melanoma

Antibody-Drug Conjugates in the Pipeline for Treatment of Melanoma: Target and Pharmacokinetic Considerations

Structure–Activity Relationship of Synthetic Linear KTS-Peptides Containing Meta-Aminobenzoic Acid as Antagonists of α1β1 Integrin with Anti-Angiogenic and Melanoma Anti-Tumor Activities

A novel mitochondria‐targeting compound exerts therapeutic effects against melanoma by inducing mitochondria‐mediated apoptosis and autophagy in vitro and in vivo